Rexahn Pharmaceuticals, Inc

Company Profile

Rexahn Pharmaceuticals, Inc had its IPO on 2005-05-23 under the ticker symbol REXN.

The company operates in the sector and industry. Rexahn Pharmaceuticals, Inc has a staff strength of 5 employees.

Stock update

Shares of Rexahn Pharmaceuticals, Inc opened at $0 at the start of the last trading session i.e. .

The stocks traded within a range of $0 - $0, and closed at $0.

This is a 0% increase from the previous day's closing price.

A total volume of 0 shares were traded at the close of the day’s session.

In the last one week, shares of Rexahn Pharmaceuticals, Inc have increased by 0%.

Rexahn Pharmaceuticals, Inc's Key Ratios

Rexahn Pharmaceuticals, Inc has a market cap of $0.009 billion, indicating a price to book ratio of 1.2966 and a price to sales ratio of 7.0794.

In the last 12-months Rexahn Pharmaceuticals, Inc’s revenue was $0.001 billion with a gross profit of $0.000 billion and an EBITDA of $-0.017 billion. The EBITDA ratio measures Rexahn Pharmaceuticals, Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Rexahn Pharmaceuticals, Inc’s operating margin was -626.1% while its return on assets stood at -32.23% with a return of equity of -67.16%.

In Q2, Rexahn Pharmaceuticals, Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Rexahn Pharmaceuticals, Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

None

Its diluted EPS in the last 12-months stands at $-2.658 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of None. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Rexahn Pharmaceuticals, Inc’s profitability.

Rexahn Pharmaceuticals, Inc stock is trading at a EV to sales ratio of 0.0065 and a EV to EBITDA ratio of 0.0211. Its price to sales ratio in the trailing 12-months stood at 7.0794.

Rexahn Pharmaceuticals, Inc stock pays annual dividends of $None per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$0.000 billion

Total Liabilities

$0.000 billion

Operating Cash Flow

$0.000 billion

Capital Expenditure

$0.000 billion

Dividend Payout Ratio

0%

Rexahn Pharmaceuticals, Inc ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

Rexahn Pharmaceuticals, Inc ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

Rexahn Pharmaceuticals, Inc’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, Rexahn Pharmaceuticals, Inc's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, Rexahn Pharmaceuticals, Inc paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price

$0

52-Week High

$4.26

52-Week Low

$1.2626

Analyst Target Price

$3

Rexahn Pharmaceuticals, Inc stock is currently trading at $0 per share. It touched a 52-week high of $4.26 and a 52-week low of $4.26. Analysts tracking the stock have a 12-month average target price of $3.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at 0.08 indicating a short percent outstanding of 0%.

Around 30.6% of the company’s stock are held by insiders while 1146.9% are held by institutions.